Fig. 5: TCRA2-2 and TCRA24 T cells kill organoids and TCRA2-2 eradicates a PDX in vivo.
From: TCR-engineered T cells targeting a shared β-catenin mutation eradicate solid tumors
a, Killing of CRC+A2+A24 and EAC organoids by TCRA2-2- or TCRA24-transduced T cells relative to mock-transduced or TCR1G4-transduced T cells (control T cells). Bars show mean ± s.e.m. of one or two independent experiments with n = 3 different PBMC donors, and each dot represents the average of one donor with n = 3 technical replicates. b, Schematic overview of the EAC PDX in vivo endometrial adenocarcinoma model; n = 7 mice per group. Figure created with BioRender.com; 15 M, 15 million. c, Tumor volume measured by calipers at the indicated time points after implantation of PDX fragments. Data are presented as mean ± s.e.m. Endpoint tumor volumes were compared among the tumor-only- and TCR1G4- and TCRA2-2-T cell-treated groups using one-way analysis of variance (ANOVA). If significant, pairwise differences were assessed by Tukey’s post hoc test; *P < 0.05; tumor only versus TCRA2-2 P = 0.0183; TCR1G4 versus TCRA2-2 P = 0.0352. d, Percentage of hCD45+ cells among all CD45+ cells (both mouse CD45+ and hCD45+) in mouse PB at the indicated time points (gating strategy in Extended Data Fig. 8a). Each data point represents an individual mouse. The data in c and d are from one experiment.
